pml school: minimal physiologically-based pharmacokinetic model for monoclonal antibodies (mabs)
Published 6 years ago • 2.1K plays • Length 47:14Download video MP4
Download video MP3
Similar videos
-
48:47
using pml to perform mechanistic pharmacokinetic modeling
-
57:56
pbpk models for mabs in paediatrics and pregnancy – current status, opportunities and challenges
-
43:18
pml school: target-mediated drug disposition
-
39:27
the physiological basis of comparative pharmacokinetics
-
49:17
pml school: metabolite kinetics
-
59:49
pbpk modeling approaches to assess risks associated with bioequivalence in drug development
-
1:37
human biology: monoclonal antibodies
-
1:41
what are monoclonal antibodies?
-
55:39
a best practice framework for applying pbpk modeling to pediatric drug development
-
59:23
first-in-human (fih) faster: the power of physiologically based pharmacokinetic (pbpk) modeling
-
1:12
what are therapeutic antibodies?
-
41:27
what does the clin pharm plan for a biologic look like?
-
36:08
pbpk modeling of antibody-drug conjugates – concept and application
-
40:30
pml school: introduction & nonlinear clearance
-
29:37
from bedside to laboratory: pre-analyticalaspects and quality of microbiological culture
-
0:36
#108: hybridoma.com
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv